Message #9 From:
NewsBot Date: August 22, 2006 04:30:00 AM
IFMX News Penn Medicine to Use InforMedix's Med-eMonitor System in Stroke Prevention Pilot Program
ROCKVILLE, Md.--(BUSINESS WIRE)--Aug. 22, 2006--
Patients Taking Anticoagulant Medication to be Placed on "Interactive Pillbox" to Help Prevent Blood Clots that Cause Stroke and Pulmonary Embolism
InforMedix Holdings, Inc. (OTCBB:IFMX), creating a new technology platform that improves medication adherence and enables patients to manage chronic illnesses at home, today announced a pilot program with the University of Pennsylvania utilizing Med-eMonitor System(TM) for patients with high risk of stroke.
Led by Drs. Stephen Kimmel and Kevin Volpp, this novel rewards-based program intends to enroll patients who are currently taking anticoagulant medication. This "blood thinner" medication is used to prevent blood clots from forming in the body that cause life-threatening strokes and pulmonary embolism (an often fatal blood clot in the lungs). Taking too little medication results in increased incidence of stroke and pulmonary embolism, while taking too much medication may cause life-threatening excessive bleeding.
Every 45 seconds in the United States, someone experiences a stroke. This fact translates into approximately 700,000 new or recurrent strokes in the Unites States each year. It is the second leading cause of mortality in the world after cardiovascular disease, the third leading cause of death in the United States, and is the leading cause of long-term disability. The annual cost of stroke related care in the U.S. will exceed $58 billion in 2006.
Kevin Volpp, M.D., Ph.D is Assistant Professor of Medicine and Health Care Systems, University of Pennsylvania School of Medicine and the Wharton School. Stephen E. Kimmel, M.D., M.S.C.E. Director, is Cardiovascular Epidemiology, Associate Professor of Medicine & Epidemiology University of Pennsylvania School of Medicine.
Dr. Bruce Kehr, Chairman and CEO of InforMedix commented, "The program we are announcing today is one of a series of initiatives we are undertaking with Penn Medicine to bring the benefits of the Med-eMonitor System to an increasingly larger population of patients in a systematic way. Penn is home of the nation's first medical school, with a global reputation for medical innovation. Med-eMonitor consistently delivers medication and care plan adherence rates of over 90% in patients suffering from congestive heart failure and schizophrenia; and the average reduction in HbA1c of 18.5%, with a p- value signifying a high degree of statistical significance, correlates with significant reductions in morbidity, mortality, and cost."
InforMedix has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and clinical drug trials markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable disease management programs, pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients' medication compliance, protocol adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in disease management and clinical drug trials programs. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 12 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB:IFMX), visit our website at www.informedix.com.
This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.
